Skip to Main Content

Latest Articles

Research Article
Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinoma
Da-Feng Lin and others
Background The prognostic value of traditional clinical indicators for locally recurrent nasopharyngeal carcinoma (lrNPC) is limited due to their inability to reflect intratumor heterogeneity. We aimed to develop a radiomic signature to reveal tumor immune heterogeneity and predict survival in lrNPC. Methods This multicenter, retrospective study included 921 patients with lrNPC. A machine ...
Editorial
Measures of physical function clarify the prognostic blur of cancer survivorship
Justin C Brown
Physical functioning and efficient mobility have been a primary emphasis of natural selection throughout human evolution ( 1 ). Physical function, such as walking, is a complex activity that requires a year to develop after birth ( 2 ). Multiple physiologic networks, such as the cardiopulmonary, neurologic, and musculoskeletal systems, work together to enable optimal physical function ( 3 ). ...
Brief Report
Adolescents and young adults (AYA) with cancer: the clinical course of COVID-19 infections
Julie A Wolfson and others
Adolescents and Young Adults (AYAs: 15-39 y) with cancer face unique vulnerabilities, yet remain under-represented on clinical trials, including adult registries of COVID-19 in cancer (AYAs: 8-12%). Thus, we leveraged the Pediatric Oncology COVID-19 Case Report (POCC) to examine the clinical course of COVID-19 among AYAs with cancer. POCC collects de-identified clinical and sociodemographic data ...
Research Article
A population-based study of COVID-19 mortality risk in US cancer patients
Kyle A Mani and others
Background In this study, we provide the largest analysis to date of a US-based cancer cohort to characterize death from COVID-19. Methods A total of 4,020,669 patients across 15 subtypes living with cancer in 2020 and included in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database were abstracted. We investigated prognostic factors for death due to ...
Research Article
Increasing power in screening trials by testing control-arm specimens: Application to multicancer detection screening
Hormuzd A Katki and others
Background Cancer screening trials have required large sample-sizes and long time-horizons to demonstrate cancer mortality reductions, the primary goal of cancer screening. We examine assumptions and potential power gains from exploiting information from testing control-arm specimens, which we call the “Intended Effect” (IE) analysis that we explain in detail herein. The IE analysis is ...

Editor's Choice & Editorials

Editor's Choice Review
The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis
Ryan S Huang and others
JNCI: Journal of the National Cancer Institute, Volume 116, Issue 3, March 2024, Pages 356–369, https://doi.org/10.1093/jnci/djad268
Background Multidisciplinary cancer conferences consist of regular meetings between diverse specialists working together to share clinical decision making in cancer care. The aim of this study was to systematically review and meta-analyze the effect of multidisciplinary cancer conference intervention on the overall survival of patients with cancer. Methods A systematic literature search was ...
Editor's Choice Article
Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers
Jing Sun and others
JNCI: Journal of the National Cancer Institute, Volume 116, Issue 4, April 2024, Pages 565–573, https://doi.org/10.1093/jnci/djad247
Background The proteome is an important reservoir of potential therapeutic targets for cancer. This study aimed to examine the causal associations between plasma proteins and cancer risk and to identify proteins with cross-cancer effects. Methods Genetic instruments for 3991 plasma proteins were extracted from a large-scale proteomic study. Summary-level data of 13 site-specific cancers were ...
Editor's Choice Article
Morphological diversity of cancer cells predicts prognosis across tumor types
Rasoul Sali and others
JNCI: Journal of the National Cancer Institute, Volume 116, Issue 4, April 2024, Pages 555–564, https://doi.org/10.1093/jnci/djad243
Background Intratumor heterogeneity drives disease progression and treatment resistance, which can lead to poor patient outcomes. Here, we present a computational approach for quantification of cancer cell diversity in routine hematoxylin-eosin–stained histopathology images. Methods We analyzed publicly available digitized whole-slide hematoxylin-eosin images for 2000 patients. Four tumor types ...
Editor's Choice Article
Trends in new and persistent opioid use in older adults with and without cancer
Laura Van Metre Baum and others
JNCI: Journal of the National Cancer Institute, Volume 116, Issue 2, February 2024, Pages 316–323, https://doi.org/10.1093/jnci/djad206
Background The impact of ongoing efforts to decrease opioid use on patients with cancer remains undefined. Our objective was to determine trends in new and additional opioid use in patients with and without cancer. Methods This retrospective cohort study used data from Surveillance, Epidemiology, and End Results program–Medicare for opioid-naive patients with solid tumor malignancies diagnosed ...
Editor's Choice Article
Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer—a real-world effectiveness study
Louise Baandrup and others
JNCI: Journal of the National Cancer Institute, Volume 116, Issue 2, February 2024, Pages 283–287, https://doi.org/10.1093/jnci/djad189
Background Human papillomavirus (HPV) vaccination has shown high efficacy against anal HPV infection and lesions in clinical trials, and the HPV prevalence and type distribution in anal precancers and cancer predict a high preventable potential for HPV vaccination. However, the real-world effectiveness of HPV vaccination against anal high-grade lesions and cancer is yet to be shown. Methods We ...
White pills on a table.

Opioids and Cancer Collection

Explore a selection of articles from JNCI and JNCI Cancer Spectrum on opioid use in cancer patients and survivors. 

Read now.

Image shows a photograph of text with the word 'diversity' highlighted in pink highlighter pen.

Diversity, Equity, and Inclusion Collection 

As a part of their Diversity, Equity, and Inclusion initiative, JNCI and JNCI Cancer Spectrum have curated a collection of articles that foreground diversity, equity, and inclusion in their research. 

Read now.

Coronavirus Spike Protein

COVID-19 Collection

JNCI and JNCI Cancer Spectrum have published a number of peer-reviewed, cancer-relevant manuscripts related to the pandemic. Explore the freely available articles in this collection.  

Read now.

Diversity, Equity, and Inclusion for the JNCI Journals

In 2022, the JNCI journals launched a DEI initiative, committing to increase diversity and inclusion of underrepresented groups in the peer review process and research dissemination. 1 year on, the teams provide an update. Read the editorial here. 

JNCI Cancer Spectrum

JNCI Cancer Spectrum

JNCI Cancer Spectrum is a peer-reviewed, open-access journal. It publishes manuscripts that describe new findings of particular significance across a full range of clinical and translational cancer research, including prevention, screening, and treatment, as well as clinically relevant epidemiologic, public health, and policy research.

Learn more about the journal 

image of JNCI mono logo

JNCI Monographs

Have you read the latest publication from JNCI Monographs?  

Read the current issue and explore the archive

jnci facebook

Facebook

Stay up to date with the latest news and content from JNCI by visiting our Facebook page.

Email alerts

Register to receive table of contents email alerts as soon as new issues of JNCI: Journal of the National Cancer Institute are published online.

Sign up

 

Developing countries initiative

Developing countries initiative

Your institution could be eligible to free or deeply discounted online access to JNCI: Journal of the National Cancer Institute through the Oxford Developing Countries Initiative.

Find out more

Committee on Publication Ethics (COPE)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)

publicationethics.org

Recommend to your library

Recommend to your library

Fill out our simple online form to recommend JNCI: Journal of the National Cancer Institute to your library.

Recommend now

Author resources

Author resources

Learn about how to submit your article, our publishing process, and tips on how to promote your article.

Find out more

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close